{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:15:10Z","timestamp":1785366910537,"version":"3.55.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802414"],"award-info":[{"award-number":["81802414"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Provincial Key Research and Development Program","award":["2019GSF108053"],"award-info":[{"award-number":["2019GSF108053"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-025-10303-0","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T18:19:29Z","timestamp":1764440369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent advances and treatment strategies in liver metastasis of pancreatic neuroendocrine tumors"],"prefix":"10.1007","volume":"44","author":[{"given":"Zhiyuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xishun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"10303_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-med-042320-011248","volume":"73","author":"A Chang","year":"2022","unstructured":"Chang, A., Sherman, S. K., Howe, J. R., & Sahai, V. (2022). Progress in the management of pancreatic neuroendocrine tumors. Annual Review of Medicine, 73, 213\u2013229. https:\/\/doi.org\/10.1146\/annurev-med-042320-011248","journal-title":"Annual Review of Medicine"},{"issue":"1","key":"10303_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi, G., Mete, O., Uccella, S., Basturk, O., La Rosa, S., Brosens, L. A. A., Ezzat, S., de Herder, W. W., Klimstra, D. S., Papotti, M., & Asa, S. L. (2022). Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocrine Pathology, 33(1), 115\u2013154. https:\/\/doi.org\/10.1007\/s12022-022-09708-2","journal-title":"Endocrine Pathology"},{"issue":"10","key":"10303_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017). Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncology, 3(10), 1335\u20131342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","journal-title":"JAMA Oncology"},{"issue":"8","key":"10303_CR4","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/cncr.28760","volume":"121","author":"A Frilling","year":"2015","unstructured":"Frilling, A., & Clift, A. K. (2015). Therapeutic strategies for neuroendocrine liver metastases. Cancer, 121(8), 1172\u20131186. https:\/\/doi.org\/10.1002\/cncr.28760","journal-title":"Cancer"},{"issue":"2","key":"10303_CR5","doi-asserted-by":"publisher","DOI":"10.21037\/cco-23-145","volume":"13","author":"JY Chang","year":"2024","unstructured":"Chang, J. Y., Ruff, S. M., & Cloyd, J. M. (2024). Treatment strategies for borderline resectable pancreatic neuroendocrine tumors: A narrative review. Chinese Clinical Oncology, 13(2), Article 25. https:\/\/doi.org\/10.21037\/cco-23-145","journal-title":"Chinese Clinical Oncology"},{"issue":"12","key":"10303_CR6","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ijc.30400","volume":"139","author":"M Riihimaki","year":"2016","unstructured":"Riihimaki, M., Hemminki, A., Sundquist, K., Sundquist, J., & Hemminki, K. (2016). The epidemiology of metastases in neuroendocrine tumors. International Journal of Cancer, 139(12), 2679\u20132686. https:\/\/doi.org\/10.1002\/ijc.30400","journal-title":"International Journal of Cancer"},{"issue":"7","key":"10303_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","volume":"27","author":"MB Sonbol","year":"2022","unstructured":"Sonbol, M. B., Mazza, G. L., Mi, L., Oliver, T., Starr, J., Gudmundsdottir, H., Cleary, S. P., Hobday, T., & Halfdanarson, T. R. (2022). Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: A SEER database analysis. The oncologist, 27(7), 573\u2013578. https:\/\/doi.org\/10.1093\/oncolo\/oyac049","journal-title":"The oncologist"},{"issue":"42","key":"10303_CR8","doi-asserted-by":"publisher","first-page":"71699","DOI":"10.18632\/oncotarget.17599","volume":"8","author":"JH Fan","year":"2017","unstructured":"Fan, J. H., Zhang, Y. Q., Shi, S. S., Chen, Y. J., Yuan, X. H., Jiang, L. M., Wang, S. M., Ma, L., He, Y. T., Feng, C. Y., Sun, X. B., Liu, Q., Deloso, K., Chi, Y., & Qiao, Y. L. (2017). A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in China. Oncotarget, 8(42), 71699\u201371708. https:\/\/doi.org\/10.18632\/oncotarget.17599","journal-title":"Oncotarget"},{"issue":"1","key":"10303_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s12885-023-10893-4","volume":"23","author":"J Li","year":"2023","unstructured":"Li, J., Huang, L., Liao, C., Liu, G., Tian, Y., & Chen, S. (2023). Two machine learning-based nomogram to predict risk and prognostic factors for liver metastasis from pancreatic neuroendocrine tumors: A multicenter study. BMC Cancer, 23(1), 529. https:\/\/doi.org\/10.1186\/s12885-023-10893-4","journal-title":"BMC Cancer"},{"issue":"3","key":"10303_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser, K. E., & Joyce, J. A. (2023). The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 41(3), 374\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2023.02.016","journal-title":"Cancer Cell"},{"issue":"1","key":"10303_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00261-6","volume":"7","author":"DI Tsilimigras","year":"2021","unstructured":"Tsilimigras, D. I., Brodt, P., Clavien, P. A., Muschel, R. J., D\u2019Angelica, M. I., Endo, I., Parks, R. W., Doyle, M., de Santibanes, E., & Pawlik, T. M. (2021). Liver metastases. Nature Reviews Disease Primers, 7(1), Article 27. https:\/\/doi.org\/10.1038\/s41572-021-00261-6","journal-title":"Nature Reviews Disease Primers"},{"issue":"4","key":"10303_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3322\/caac.21840","volume":"74","author":"A Chauhan","year":"2024","unstructured":"Chauhan, A., Chan, K., Halfdanarson, T. R., Bellizzi, A. M., Rindi, G., O\u2019Toole, D., Ge, P. S., Jain, D., Dasari, A., Anaya, D. A., Bergsland, E., Mittra, E., Wei, A. C., Hope, T. A., Kendi, A. T., Thomas, S. M., Flem, S., Brierley, J., Asare, E. A., \u2026 Shi, C. (2024). Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA: A Cancer Journal for Clinicians, 74(4), 359\u2013367. https:\/\/doi.org\/10.3322\/caac.21840","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"6","key":"10303_CR13","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1097\/SLA.0000000000004039","volume":"275","author":"XF Zhang","year":"2022","unstructured":"Zhang, X. F., Xue, F., Wu, Z., Lopez-Aguiar, A. G., Poultsides, G., Makris, E., Rocha, F., Kanji, Z., Weber, S., Fisher, A., Fields, R., Krasnick, B. A., Idrees, K., Smith, P. M., Cho, C., Beems, M., Lyu, Y., Maithel, S. K., & Pawlik, T. M. (2022). Development and validation of a modified eighth AJCC staging system for primary pancreatic neuroendocrine tumors. Annals of Surgery, 275(6), e773\u2013e780. https:\/\/doi.org\/10.1097\/SLA.0000000000004039","journal-title":"Annals of Surgery"},{"issue":"2","key":"10303_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1158\/1078-0432.CCR-16-1113","volume":"23","author":"AD Singhi","year":"2017","unstructured":"Singhi, A. D., Liu, T. C., Roncaioli, J. L., Cao, D., Zeh, H. J., Zureikat, A. H., Tsung, A., Marsh, J. W., Lee, K. K., Hogg, M. E., Bahary, N., Brand, R. E., McGrath, K. M., Slivka, A., Cressman, K. L., Fuhrer, K., & O\u2019Sullivan, R. J. (2017). Alternative lengthening of telomeres and loss of DAXX\/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clinical Cancer Research, 23(2), 600\u2013609. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1113","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10303_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41591-019-0493-4","volume":"25","author":"P Cejas","year":"2019","unstructured":"Cejas, P., Drier, Y., Dreijerink, K. M. A., Brosens, L. A. A., Deshpande, V., Epstein, C. B., Conemans, E. B., Morsink, F. H. M., Graham, M. K., Valk, G. D., Vriens, M. R., Castillo, C. F., Ferrone, C. R., Adar, T., Bowden, M., Whitton, H. J., Da Silva, A., Font-Tello, A., Long, H. W., \u2026 Shivdasani, R. A. (2019). Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors. Nature Medicine, 25(8), 1260\u20131265. https:\/\/doi.org\/10.1038\/s41591-019-0493-4","journal-title":"Nature Medicine"},{"issue":"5","key":"10303_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng, W. M., Brosens, L. A. A., Kim, J. Y., O\u2019Sullivan, R., Sung, Y. N., Liu, T. C., Cao, D., Heayn, M., Brosnan-Cashman, J., An, S., Morsink, F. H. M., Heidsma, C. M., Valk, G. D., Vriens, M. R., van Nieveen Dijkum, E., Offerhaus, G. J. A., Dreijerink, K. M. A., Zeh, H., Zureikat, A. H., \u2026 Singhi, A. D. (2022). Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut, 71(5), 961\u2013973. https:\/\/doi.org\/10.1136\/gutjnl-2020-322595","journal-title":"Gut"},{"issue":"23","key":"10303_CR17","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1158\/1078-0432.CCR-19-1026","volume":"25","author":"D Reidy-Lagunes","year":"2019","unstructured":"Reidy-Lagunes, D., Pandit-Taskar, N., O\u2019Donoghue, J. A., Krebs, S., Staton, K. D., Lyashchenko, S. K., Lewis, J. S., Raj, N., Gonen, M., Lohrmann, C., Bodei, L., & Weber, W. A. (2019). Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist (177)Lu-Satoreotide Tetraxetan. Clinical Cancer Research, 25(23), 6939\u20136947. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1026","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10303_CR18","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00259-016-3486-2","volume":"44","author":"P Brunner","year":"2017","unstructured":"Brunner, P., Jorg, A. C., Glatz, K., Bubendorf, L., Radojewski, P., Umlauft, M., Marincek, N., Spanjol, P. M., Krause, T., Dumont, R. A., Maecke, H. R., Muller-Brand, J., Briel, M., Schmitt, A., Perren, A., & Walter, M. A. (2017). The prognostic and predictive value of sstr(2)-immunohistochemistry and sstr(2)-targeted imaging in neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 44(3), 468\u2013475. https:\/\/doi.org\/10.1007\/s00259-016-3486-2","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"3","key":"10303_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100065","volume":"36","author":"SE Umetsu","year":"2023","unstructured":"Umetsu, S. E., Kakar, S., Basturk, O., Kim, G. E., Chatterjee, D., Wen, K. W., Hale, G., Shafizadeh, N., Cho, S. J., Whitman, J., Gill, R. M., Jones, K. D., Navale, P., Bergsland, E., Klimstra, D., & Joseph, N. M. (2023). Integrated genomic and clinicopathologic approach distinguishes pancreatic grade 3 neuroendocrine tumor from neuroendocrine carcinoma and identifies a subset with molecular overlap. Modern Pathology, 36(3), Article 100065. https:\/\/doi.org\/10.1016\/j.modpat.2022.100065","journal-title":"Modern Pathology"},{"issue":"1","key":"10303_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-020-01469-0","volume":"4","author":"V Lakis","year":"2021","unstructured":"Lakis, V., Lawlor, R. T., Newell, F., Patch, A. M., Mafficini, A., Sadanandam, A., Koufariotis, L. T., Johnston, R. L., Leonard, C., Wood, S., Rusev, B., Corbo, V., Luchini, C., Cingarlini, S., Landoni, L., Salvia, R., Milella, M., Chang, D., Bailey, P., \u2026 Scarpa, A. (2021). DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 4(1), Article 155. https:\/\/doi.org\/10.1038\/s42003-020-01469-0","journal-title":"Communications Biology"},{"issue":"1","key":"10303_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00659-x","volume":"8","author":"B Deschler-Baier","year":"2024","unstructured":"Deschler-Baier, B., Krebs, M., Kroiss, M., Chatterjee, M., Gundel, D., Kestler, C., Kerscher, A., Kunzmann, V., Appenzeller, S., Maurus, K., Rosenwald, A., Bargou, R., Gerhard-Hartmann, E., & Venkataramani, V. (2024). Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch. NPJ Precision Oncology, 8(1), Article 167. https:\/\/doi.org\/10.1038\/s41698-024-00659-x","journal-title":"NPJ Precision Oncology"},{"key":"10303_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101911","volume":"81","author":"AY Li","year":"2019","unstructured":"Li, A. Y., McCusker, M. G., Russo, A., Scilla, K. A., Gittens, A., Arensmeyer, K., Mehra, R., Adamo, V., & Rolfo, C. (2019). RET fusions in solid tumors. Cancer Treatment Reviews, 81, Article 101911. https:\/\/doi.org\/10.1016\/j.ctrv.2019.101911","journal-title":"Cancer Treatment Reviews"},{"issue":"17","key":"10303_CR23","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/0008-5472.CAN-19-2232","volume":"80","author":"Y Yamauchi","year":"2020","unstructured":"Yamauchi, Y., Kodama, Y., Shiokawa, M., Kakiuchi, N., Marui, S., Kuwada, T., Sogabe, Y., Tomono, T., Mima, A., Morita, T., Matsumori, T., Ueda, T., Tsuda, M., Nishikawa, Y., Kuriyama, K., Sakuma, Y., Ota, Y., Maruno, T., Uza, N., \u2026 Seno, H. (2020). Rb and p53 execute distinct roles in the development of pancreatic neuroendocrine tumors. Cancer Research, 80(17), 3620\u20133630. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2232","journal-title":"Cancer Research"},{"issue":"4","key":"10303_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12022-024-09835-y","volume":"35","author":"NM Joseph","year":"2024","unstructured":"Joseph, N. M., Umetsu, S. E., Kim, G. E., Terry, M., Perry, A., Bergsland, E., & Kakar, S. (2024). Progression of low-grade neuroendocrine tumors (NET) to high-grade neoplasms harboring the NEC-like co-alteration of RB1 and TP53. Endocrine Pathology, 35(4), 325\u2013337. https:\/\/doi.org\/10.1007\/s12022-024-09835-y","journal-title":"Endocrine Pathology"},{"issue":"6","key":"10303_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189184","volume":"1879","author":"J Jiang","year":"2024","unstructured":"Jiang, J., Xu, J., Ji, S., Yu, X., & Chen, J. (2024). Unraveling the mysteries of MGMT: Implications for neuroendocrine tumors. Biochimica et Biophysica Acta - Reviews on Cancer, 1879(6), Article 189184. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189184","journal-title":"Biochimica et Biophysica Acta - Reviews on Cancer"},{"issue":"35","key":"10303_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202308417","volume":"11","author":"J Xu","year":"2024","unstructured":"Xu, J., Lou, X., Wang, F., Zhang, W., Xu, X., Ye, Z., Zhuo, Q., Wang, Y., Jing, D., Fan, G., Chen, X., Zhang, Y., Zhou, C., Chen, J., Qin, Y., Yu, X., & Ji, S. (2024). MEN1 deficiency-driven activation of the beta-catenin-MGMT axis promotes pancreatic neuroendocrine tumor growth and confers temozolomide resistance. Advanced Science (Weinheim), 11(35), Article e2308417. https:\/\/doi.org\/10.1002\/advs.202308417","journal-title":"Advanced Science (Weinheim)"},{"issue":"6","key":"10303_CR27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G., Tomassetti, P., Pavel, M. E., Hoosen, S., Haas, T., Lincy, J., Lebwohl, D., & Oberg, K. (2011). Everolimus for advanced pancreatic neuroendocrine tumors. The New England Journal of Medicine, 364(6), 514\u2013523. https:\/\/doi.org\/10.1056\/NEJMoa1009290","journal-title":"The New England Journal of Medicine"},{"key":"10303_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084041","author":"F Marini","year":"2021","unstructured":"Marini, F., Giusti, F., Tonelli, F., & Brandi, M. L. (2021). Pancreatic neuroendocrine neoplasms in multiple endocrine neoplasia type 1. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms22084041","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10303_CR29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ecl.2017.04.008","volume":"46","author":"R Yu","year":"2017","unstructured":"Yu, R., & Wachsman, A. (2017). Imaging of neuroendocrine tumors: Indications, interpretations, limits, and pitfalls. Endocrinology and Metabolism Clinics of North America, 46(3), 795\u2013814. https:\/\/doi.org\/10.1016\/j.ecl.2017.04.008","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"3","key":"10303_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.mric.2018.03.010","volume":"26","author":"GC Lo","year":"2018","unstructured":"Lo, G. C., & Kambadakone, A. (2018). MR imaging of pancreatic neuroendocrine tumors. Magnetic Resonance Imaging Clinics of North America, 26(3), 391\u2013403. https:\/\/doi.org\/10.1016\/j.mric.2018.03.010","journal-title":"Magnetic Resonance Imaging Clinics of North America"},{"issue":"9","key":"10303_CR31","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.7150\/thno.98053","volume":"14","author":"A Akhavanallaf","year":"2024","unstructured":"Akhavanallaf, A., Joshi, S., Mohan, A., Worden, F. P., Krauss, J. C., Zaidi, H., Frey, K., Suresh, K., Dewaraja, Y. K., & Wong, K. K. (2024). Enhancing precision: A predictive model for (177)Lu-DOTATATE treatment response in neuroendocrine tumors using quantitative (68)Ga-DOTATATE PET and clinicopathological biomarkers. Theranostics, 14(9), 3708\u20133718. https:\/\/doi.org\/10.7150\/thno.98053","journal-title":"Theranostics"},{"issue":"8","key":"10303_CR32","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.7150\/thno.96762","volume":"14","author":"G Hou","year":"2024","unstructured":"Hou, G., Cheng, X., Yang, Y., Zhao, D., Wang, G., Zhao, H., Zheng, R., Wang, X., Chen, X., Chi, Y., & Zhang, J. (2024). Diagnostic performance and clinical impact of (18)F-AlF-NOTA-octreotide in a large cohort of patients with neuroendocrine neoplasms: A prospective single-center study. Theranostics, 14(8), 3213\u20133220. https:\/\/doi.org\/10.7150\/thno.96762","journal-title":"Theranostics"},{"issue":"1","key":"10303_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13359","volume":"36","author":"V Ambrosini","year":"2024","unstructured":"Ambrosini, V., Caplin, M., Castano, J. P., Christ, E., Denecke, T., Deroose, C. M., Dromain, C., Falconi, M., Grozinsky-Glasberg, S., Hicks, R. J., Hofland, J., Kjaer, A., Knigge, U. P., Kos-Kudla, B., Koumarianou, A., Krishna, B., Lamarca, A., Pavel, M., Reed, N. S., \u2026 Prasad, V. (2024). Use and perceived utility of [(18) F]FDG PET\/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022. Journal of Neuroendocrinology, 36(1), Article e13359. https:\/\/doi.org\/10.1111\/jne.13359","journal-title":"Journal of Neuroendocrinology"},{"issue":"2","key":"10303_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/bjs.6468","volume":"96","author":"A Frilling","year":"2009","unstructured":"Frilling, A., Li, J., Malamutmann, E., Schmid, K. W., Bockisch, A., & Broelsch, C. E. (2009). Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. British Journal of Surgery, 96(2), 175\u2013184. https:\/\/doi.org\/10.1002\/bjs.6468","journal-title":"British Journal of Surgery"},{"issue":"7643","key":"10303_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature21063","volume":"543","author":"A Scarpa","year":"2017","unstructured":"Scarpa, A., Chang, D. K., Nones, K., Corbo, V., Patch, A. M., Bailey, P., Lawlor, R. T., Johns, A. L., Miller, D. K., Mafficini, A., Rusev, B., Scardoni, M., Antonello, D., Barbi, S., Sikora, K. O., Cingarlini, S., Vicentini, C., McKay, S., Quinn, M. C., \u2026 Grimmond, S. M. (2017). Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), 65\u201371. https:\/\/doi.org\/10.1038\/nature21063","journal-title":"Nature"},{"issue":"1","key":"10303_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.surg.2020.04.034","volume":"169","author":"CG Tran","year":"2021","unstructured":"Tran, C. G., Scott, A. T., Li, G., Sherman, S. K., Ear, P. H., & Howe, J. R. (2021). Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling. Surgery, 169(1), 155\u2013161. https:\/\/doi.org\/10.1016\/j.surg.2020.04.034","journal-title":"Surgery"},{"key":"10303_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216769","volume":"588","author":"Z Ye","year":"2024","unstructured":"Ye, Z., Li, Q., Hu, Y., Hu, H., Xu, J., Guo, M., Zhang, W., Lou, X., Wang, Y., Gao, H., Jing, D., Fan, G., Qin, Y., Zhang, Y., Chen, X., Chen, J., Xu, X., Yu, X., Liu, M., & Ji, S. (2024). The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes. Cancer Letters, 588, Article 216769. https:\/\/doi.org\/10.1016\/j.canlet.2024.216769","journal-title":"Cancer Letters"},{"issue":"8","key":"10303_CR38","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1245\/s10434-014-4145-0","volume":"22","author":"S Singh","year":"2015","unstructured":"Singh, S., Dey, C., Kennecke, H., Kocha, W., Maroun, J., Metrakos, P., Mukhtar, T., Pasieka, J., Rayson, D., Rowsell, C., Sideris, L., Wong, R., & Law, C. (2015). Consensus recommendations for the diagnosis and management of pancreatic neuroendocrine tumors: Guidelines from a Canadian National Expert Group. Annals of Surgical Oncology, 22(8), 2685\u20132699. https:\/\/doi.org\/10.1245\/s10434-014-4145-0","journal-title":"Annals of Surgical Oncology"},{"issue":"5","key":"10303_CR39","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3892\/ijo.2016.3711","volume":"49","author":"K Jin","year":"2016","unstructured":"Jin, K., Xu, J., Chen, J., Chen, M., Chen, R., Chen, Y., Chen, Z., Cheng, B., Chi, Y., Feng, S. T., Fu, D., Hou, B., Huang, D., Huang, H., Huang, Q., Li, J., Li, Y., Liang, H., Lin, R., \u2026 Yu, X. (2016). Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET). International Journal of Oncology, 49(5), 1991\u20132000. https:\/\/doi.org\/10.3892\/ijo.2016.3711","journal-title":"International Journal of Oncology"},{"issue":"4","key":"10303_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000486096","volume":"106","author":"WT Zandee","year":"2018","unstructured":"Zandee, W. T., & de Herr, W. W. (2018). The evolution of neuroendocrine tumor treatment reflected by ENETS Guidelines. Neuroendocrinology, 106(4), 357\u2013365. https:\/\/doi.org\/10.1159\/000486096","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10303_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.surg.2018.09.006","volume":"165","author":"JF Tierney","year":"2019","unstructured":"Tierney, J. F., Chivukula, S. V., Wang, X., Pappas, S. G., Schadde, E., Hertl, M., Poirier, J., & Keutgen, X. M. (2019). Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery, 165(3), 644\u2013651. https:\/\/doi.org\/10.1016\/j.surg.2018.09.006","journal-title":"Surgery"},{"issue":"4","key":"10303_CR42","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.surg.2013.12.024","volume":"155","author":"E Bertani","year":"2014","unstructured":"Bertani, E., Fazio, N., Botteri, E., Chiappa, A., Falconi, M., Grana, C., Bodei, L., Papis, D., Spada, F., Bazolli, B., & Andreoni, B. (2014). Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: Possible indications for a multimodal approach. Surgery, 155(4), 607\u2013614. https:\/\/doi.org\/10.1016\/j.surg.2013.12.024","journal-title":"Surgery"},{"issue":"2","key":"10303_CR43","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejso.2016.09.011","volume":"43","author":"E Bertani","year":"2017","unstructured":"Bertani, E., Fazio, N., Radice, D., Zardini, C., Spinoglio, G., Chiappa, A., Ribero, D., Biffi, R., Partelli, S., & Falconi, M. (2017). Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. European Journal of Surgical Oncology, 43(2), 372\u2013379. https:\/\/doi.org\/10.1016\/j.ejso.2016.09.011","journal-title":"European Journal of Surgical Oncology"},{"key":"10303_CR44","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jss.2019.04.002","volume":"243","author":"H Ye","year":"2019","unstructured":"Ye, H., Xu, H. L., Shen, Q., Zheng, Q., & Chen, P. (2019). Palliative resection of primary tumor in metastatic nonfunctioning pancreatic neuroendocrine tumors. Journal of Surgical Research, 243, 578\u2013587. https:\/\/doi.org\/10.1016\/j.jss.2019.04.002","journal-title":"Journal of Surgical Research"},{"issue":"3","key":"10303_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.hpb.2017.10.014","volume":"20","author":"S Partelli","year":"2018","unstructured":"Partelli, S., Cirocchi, R., Rancoita, P. M. V., Muffatti, F., Andreasi, V., Crippa, S., Tamburrino, D., & Falconi, M. (2018). A systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. HPB, 20(3), 197\u2013203. https:\/\/doi.org\/10.1016\/j.hpb.2017.10.014","journal-title":"HPB"},{"issue":"1","key":"10303_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11605-016-3270-4","volume":"21","author":"L Prakash","year":"2017","unstructured":"Prakash, L., Bhosale, P., Cloyd, J., Kim, M., Parker, N., Yao, J., Dasari, A., Halperin, D., Aloia, T., Lee, J. E., Vauthey, J. N., Fleming, J. B., & Katz, M. H. (2017). Role of fluorouracil, doxorubicin, and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors. Journal of Gastrointestinal Surgery, 21(1), 155\u2013163. https:\/\/doi.org\/10.1007\/s11605-016-3270-4","journal-title":"Journal of Gastrointestinal Surgery"},{"key":"10303_CR47","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.2147\/CIA.S209428","volume":"14","author":"J Zhang","year":"2019","unstructured":"Zhang, J., Peng, C. S., & Tian, Y. H. (2019). Primary site surgery for elderly patients with distant metastatic pancreatic neuroendocrine tumor: To do or not to do? Clinical Interventions in Aging, 14, 1419\u20131432. https:\/\/doi.org\/10.2147\/CIA.S209428","journal-title":"Clinical Interventions in Aging"},{"key":"10303_CR48","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/OTT.S158171","volume":"11","author":"B Zhou","year":"2018","unstructured":"Zhou, B., Zhan, C., Ding, Y., Yan, S., & Zheng, S. (2018). Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: A systematic review and meta-analysis. OncoTargets and Therapy, 11, 975\u2013982. https:\/\/doi.org\/10.2147\/OTT.S158171","journal-title":"OncoTargets and Therapy"},{"issue":"7","key":"10303_CR49","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/jso.26618","volume":"124","author":"H Gudmundsdottir","year":"2021","unstructured":"Gudmundsdottir, H., Graham, R. P., Sonbol, M. B., Smoot, R. L., Truty, M. J., Kendrick, M. L., Nagorney, D. M., Habermann, E. B., Halfdanarson, T. R., & Cleary, S. P. (2021). Multifocality is not associated with worse survival in sporadic pancreatic neuroendocrine tumors. Journal of Surgical Oncology, 124(7), 1077\u20131084. https:\/\/doi.org\/10.1002\/jso.26618","journal-title":"Journal of Surgical Oncology"},{"issue":"3","key":"10303_CR50","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/SLA.0000000000003461","volume":"270","author":"MY Zaidi","year":"2019","unstructured":"Zaidi, M. Y., Lopez-Aguiar, A. G., Switchenko, J. M., Lipscomb, J., Andreasi, V., Partelli, S., Gamboa, A. C., Lee, R. M., Poultsides, G. A., Dillhoff, M., Rocha, F. G., Idrees, K., Cho, C. S., Weber, S. M., Fields, R. C., Staley, C. A., 3rd., Falconi, M., & Maithel, S. K. (2019). A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: An international study of 1006 patients. Annals of Surgery, 270(3), 422\u2013433. https:\/\/doi.org\/10.1097\/SLA.0000000000003461","journal-title":"Annals of Surgery"},{"key":"10303_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101630","author":"A Lamarca","year":"2019","unstructured":"Lamarca, A., Clouston, H., Barriuso, J., McNamara, M. G., Frizziero, M., Mansoor, W., Hubner, R. A., Manoharan, P., O\u2019Dwyer, S., & Valle, J. W. (2019). Follow-up recommendations after curative resection of well-differentiated neuroendocrine tumours: Review of current evidence and clinical practice. Journal of Clinical Medicine. https:\/\/doi.org\/10.3390\/jcm8101630","journal-title":"Journal of Clinical Medicine"},{"issue":"4","key":"10303_CR52","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00535-021-01777-0","volume":"56","author":"WQ Wang","year":"2021","unstructured":"Wang, W. Q., Zhang, W. H., Gao, H. L., Huang, D., Xu, H. X., Li, S., Li, T. J., Xu, S. S., Li, H., Long, J., Ye, L. Y., Wu, C. T., Han, X., Wang, X. H., Liu, L., & Yu, X. J. (2021). A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors. Journal of Gastroenterology, 56(4), 395\u2013405. https:\/\/doi.org\/10.1007\/s00535-021-01777-0","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10303_CR53","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5858\/arpa.2021-0475-OA","volume":"147","author":"B Ahn","year":"2023","unstructured":"Ahn, B., Kim, J. Y., & Hong, S. M. (2023). Combined infiltrative macroscopic growth pattern and infiltrative microscopic tumor border status Is a novel surrogate marker of poor prognosis in patients with pancreatic neuroendocrine tumor. Archives of Pathology & Laboratory Medicine, 147(1), 100\u2013116. https:\/\/doi.org\/10.5858\/arpa.2021-0475-OA","journal-title":"Archives of Pathology & Laboratory Medicine"},{"issue":"5","key":"10303_CR54","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1245\/s10434-019-08049-5","volume":"27","author":"E Merola","year":"2020","unstructured":"Merola, E., Rinke, A., Partelli, S., Gress, T. M., Andreasi, V., Kollar, A., Perren, A., Christ, E., Panzuto, F., Pascher, A., Jann, H., Arsenic, R., Cremer, B., Kaemmerer, D., Kump, P., Lipp, R. W., Agaimy, A., Wiedenmann, B., Falconi, M., & Pavel, M. E. (2020). Surgery with radical intent: Is there an indication for G3 neuroendocrine neoplasms? Annals of Surgical Oncology, 27(5), 1348\u20131355. https:\/\/doi.org\/10.1245\/s10434-019-08049-5","journal-title":"Annals of Surgical Oncology"},{"issue":"5","key":"10303_CR55","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1245\/s10434-019-07252-8","volume":"26","author":"T Yoshida","year":"2019","unstructured":"Yoshida, T., Hijioka, S., Hosoda, W., Ueno, M., Furukawa, M., Kobayashi, N., Ikeda, M., Ito, T., Kodama, Y., Morizane, C., Notohara, K., Taguchi, H., Kitano, M., Yane, K., Tsuchiya, Y., Komoto, I., Tanaka, H., Tsuji, A., Hashigo, S., \u2026 Mizuno, N. (2019). Surgery for pancreatic neuroendocrine tumor G3 and carcinoma G3 should be considered separately. Annals of Surgical Oncology, 26(5), 1385\u20131393. https:\/\/doi.org\/10.1245\/s10434-019-07252-8","journal-title":"Annals of Surgical Oncology"},{"issue":"9","key":"10303_CR56","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.ejso.2017.04.010","volume":"43","author":"RB Galleberg","year":"2017","unstructured":"Galleberg, R. B., Knigge, U., Tiensuu Janson, E., Vestermark, L. W., Haugvik, S. P., Ladekarl, M., Langer, S. W., Gronbaek, H., Osterlund, P., Hjortland, G. O., Assmus, J., Tang, L., Perren, A., & Sorbye, H. (2017). Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology, 43(9), 1682\u20131689. https:\/\/doi.org\/10.1016\/j.ejso.2017.04.010","journal-title":"European Journal of Surgical Oncology"},{"issue":"1","key":"10303_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","volume":"49","author":"JR Howe","year":"2020","unstructured":"Howe, J. R., Merchant, N. B., Conrad, C., Keutgen, X. M., Hallet, J., Drebin, J. A., Minter, R. M., Lairmore, T. C., Tseng, J. F., Zeh, H. J., Libutti, S. K., Singh, G., Lee, J. E., Hope, T. A., Kim, M. K., Menda, Y., Halfdanarson, T. R., Chan, J. A., & Pommier, R. F. (2020). The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas, 49(1), 1\u201333. https:\/\/doi.org\/10.1097\/MPA.0000000000001454","journal-title":"Pancreas"},{"issue":"6","key":"10303_CR58","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3760\/cma.j.cn112139-20210319-00135","volume":"59","author":"WM Wu","year":"2021","unstructured":"Wu, W. M., Chen, J., Bai, C. M., Chi, Y., Du, Y. Q., Feng, S. T., Huo, L., Jiang, Y. X., Li, J. N., Lou, W. H., Luo, J., Shao, C. H., Shen, L., Wang, F., Wang, L. W., Wang, O., Wang, Y., Wu, H. W., Xing, X. P., \u2026 Chinese Pancreatic Surgery Association CSoSCMA. (2021). The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). Zhonghua Wai Ke Za Zhi, 59(6), 401\u2013421. https:\/\/doi.org\/10.3760\/cma.j.cn112139-20210319-00135","journal-title":"Zhonghua Wai Ke Za Zhi"},{"issue":"10","key":"10303_CR59","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1111\/ajt.13831","volume":"16","author":"V Mazzaferro","year":"2016","unstructured":"Mazzaferro, V., Sposito, C., Coppa, J., Miceli, R., Bhoori, S., Bongini, M., Camerini, T., Milione, M., Regalia, E., Spreafico, C., Gangeri, L., Buzzoni, R., de Braud, F. G., De Feo, T., & Mariani, L. (2016). The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. American Journal of Transplantation, 16(10), 2892\u20132902. https:\/\/doi.org\/10.1111\/ajt.13831","journal-title":"American Journal of Transplantation"},{"issue":"5","key":"10303_CR60","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/SLA.0b013e31828ee17c","volume":"257","author":"YP Le Treut","year":"2013","unstructured":"Le Treut, Y. P., Gregoire, E., Klempnauer, J., Belghiti, J., Jouve, E., Lerut, J., Castaing, D., Soubrane, O., Boillot, O., Mantion, G., Homayounfar, K., Bustamante, M., Azoulay, D., Wolf, P., Krawczyk, M., Pascher, A., Suc, B., Chiche, L., de Urbina, J. O., \u2026 For, E. (2013). Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: A 213-case European liver transplant registry study. Annals of Surgery, 257(5), 807\u2013815. https:\/\/doi.org\/10.1097\/SLA.0b013e31828ee17c","journal-title":"Annals of Surgery"},{"issue":"6","key":"10303_CR61","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jhep.2020.08.015","volume":"73","author":"PD Line","year":"2020","unstructured":"Line, P. D., & Dueland, S. (2020). Liver transplantation for secondary liver tumours: The difficult balance between survival and recurrence. Journal of Hepatology, 73(6), 1557\u20131562. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.015","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10303_CR62","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.surg.2017.05.006","volume":"162","author":"D Moris","year":"2017","unstructured":"Moris, D., Tsilimigras, D. I., Ntanasis-Stathopoulos, I., Beal, E. W., Felekouras, E., Vernadakis, S., Fung, J. J., & Pawlik, T. M. (2017). Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery, 162(3), 525\u2013536. https:\/\/doi.org\/10.1016\/j.surg.2017.05.006","journal-title":"Surgery"},{"issue":"4","key":"10303_CR63","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2007.07.004","volume":"47","author":"V Mazzaferro","year":"2007","unstructured":"Mazzaferro, V., Pulvirenti, A., & Coppa, J. (2007). Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation? Journal of Hepatology, 47(4), 460\u2013466. https:\/\/doi.org\/10.1016\/j.jhep.2007.07.004","journal-title":"Journal of Hepatology"},{"key":"10303_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1001163","volume":"12","author":"ESM Fernandes","year":"2022","unstructured":"Fernandes, E. S. M., Kyt, C. V. G., de Mello, F. P. T., Pimentel, L. S., Andrade, R. O., Girao, C., Cesar, C., Siqueira, M., Monachesi, M. E., Brito, A., de Tavares Sousa, C. C., Andraus, W., & Torres, O. J. M. (2022). Liver transplantation in gastroenteropancreatic neuroendocrine tumors. Frontiers in Oncology, 12, Article 1001163. https:\/\/doi.org\/10.3389\/fonc.2022.1001163","journal-title":"Frontiers in Oncology"},{"issue":"7","key":"10303_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13176","volume":"34","author":"E Thiis-Evensen","year":"2022","unstructured":"Thiis-Evensen, E., Kjellman, M., Knigge, U., Gronbaek, H., Schalin-Jantti, C., Welin, S., Sorbye, H., Del Pilar Schneider, M., Belusa, R., & Nordic NETBG. (2022). Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors and differentiation from small intestinal neuroendocrine tumors. Journal of Neuroendocrinology, 34(7), Article e13176. https:\/\/doi.org\/10.1111\/jne.13176","journal-title":"Journal of Neuroendocrinology"},{"issue":"6","key":"10303_CR66","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1097\/SLA.0000000000004262","volume":"274","author":"QC Chen","year":"2021","unstructured":"Chen, Q. C., Zheng, Q. W., Luo, S., & Zhao, H. (2021). Comment on \u201cResection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment.\u201d Annals of Surgery, 274(6), e758\u2013e759. https:\/\/doi.org\/10.1097\/SLA.0000000000004262","journal-title":"Annals of Surgery"},{"issue":"6","key":"10303_CR67","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1245\/s10434-018-6468-8","volume":"25","author":"JM Cloyd","year":"2018","unstructured":"Cloyd, J. M., Omichi, K., Mizuno, T., Kawaguchi, Y., Tzeng, C. D., Conrad, C., Chun, Y. S., Aloia, T. A., Katz, M. H. G., Lee, J. E., Halperin, D., Yao, J., Vauthey, J. N., & Dasari, A. (2018). Preoperative fluorouracil, doxorubicin, and streptozocin for the treatment of pancreatic neuroendocrine liver metastases. Annals of Surgical Oncology, 25(6), 1709\u20131715. https:\/\/doi.org\/10.1245\/s10434-018-6468-8","journal-title":"Annals of Surgical Oncology"},{"issue":"5","key":"10303_CR68","doi-asserted-by":"publisher","DOI":"10.1177\/1073274817729076","volume":"24","author":"CM Ambe","year":"2017","unstructured":"Ambe, C. M., Nguyen, P., Centeno, B. A., Choi, J., Strosberg, J., Kvols, L., Hodul, P., Hoffe, S., & Malafa, M. P. (2017). Multimodality management of \u201cborderline resectable\u201d pancreatic neuroendocrine tumors: Report of a single-institution experience. Cancer Control, 24(5), Article 1073274817729076. https:\/\/doi.org\/10.1177\/1073274817729076","journal-title":"Cancer Control"},{"issue":"3","key":"10303_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13425","volume":"37","author":"R Kashyap","year":"2024","unstructured":"Kashyap, R., Raja, S., Adusumilli, A., Gopireddy, M. M. R., Loveday, B. P. T., Alipour, R., & Kong, G. (2024). Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro-entero-pancreatic neuroendocrine neoplasms: A scoping review. Journal of Neuroendocrinology, , Article e13425. https:\/\/doi.org\/10.1111\/jne.13425","journal-title":"Journal of Neuroendocrinology"},{"key":"10303_CR70","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae178","author":"S Partelli","year":"2024","unstructured":"Partelli, S., Landoni, L., Bartolomei, M., Zerbi, A., Grana, C. M., Boggi, U., Butturini, G., Casadei, R., Salvia, R., & Falconi, M. (2024). Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): Multicentre phase II study. British Journal of Surgery. https:\/\/doi.org\/10.1093\/bjs\/znae178","journal-title":"British Journal of Surgery"},{"issue":"2","key":"10303_CR71","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12022-020-09623-4","volume":"31","author":"M Schiavo Lena","year":"2020","unstructured":"Schiavo Lena, M., Partelli, S., Castelli, P., Andreasi, V., Smart, C. E., Pisa, E., Bartolomei, M., Bertani, E., Zamboni, G., Falconi, M., & Doglioni, C. (2020). Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT). Endocrine Pathology, 31(2), 119\u2013131. https:\/\/doi.org\/10.1007\/s12022-020-09623-4","journal-title":"Endocrine Pathology"},{"issue":"1","key":"10303_CR72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ajco.12438","volume":"12","author":"M Pericleous","year":"2016","unstructured":"Pericleous, M., Caplin, M. E., Tsochatzis, E., Yu, D., Morgan-Rowe, L., & Toumpanakis, C. (2016). Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes. Asia-Pacific Journal of Clinical Oncology, 12(1), 61\u201369. https:\/\/doi.org\/10.1111\/ajco.12438","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"6","key":"10303_CR73","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.surg.2010.09.014","volume":"148","author":"HY Akyildiz","year":"2010","unstructured":"Akyildiz, H. Y., Mitchell, J., Milas, M., Siperstein, A., & Berber, E. (2010). Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: Long-term follow-up. Surgery, 148(6), 1288\u20131293. https:\/\/doi.org\/10.1016\/j.surg.2010.09.014","journal-title":"Surgery"},{"issue":"4","key":"10303_CR74","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.suronc.2012.07.001","volume":"21","author":"TX Yang","year":"2012","unstructured":"Yang, T. X., Chua, T. C., & Morris, D. L. (2012). Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - A systematic review. Surgical Oncology, 21(4), 299\u2013308. https:\/\/doi.org\/10.1016\/j.suronc.2012.07.001","journal-title":"Surgical Oncology"},{"key":"10303_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061478","author":"AR Siebenhuner","year":"2022","unstructured":"Siebenhuner, A. R., Langheinrich, M., Friemel, J., Schafer, N., Eshmuminov, D., & Lehmann, K. (2022). Orchestrating treatment modalities in metastatic pancreatic neuroendocrine tumors-need for a conductor. Cancers. https:\/\/doi.org\/10.3390\/cancers14061478","journal-title":"Cancers"},{"key":"10303_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020309","author":"L Chen","year":"2025","unstructured":"Chen, L., Yang, D., Yusufu, Y., Liu, H., Liu, M., Lin, Y., Luo, Y., He, Q., Chen, M., Zeng, Z., Zhang, N., & Wang, Y. (2025). Trans-arterial embolization for liver metastases of gastroenteropancreatic neuroendocrine tumors: Response indicates survival benefit? Cancers. https:\/\/doi.org\/10.3390\/cancers17020309","journal-title":"Cancers"},{"issue":"1","key":"10303_CR77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000111037","volume":"87","author":"T Steinmuller","year":"2008","unstructured":"Steinmuller, T., Kianmanesh, R., Falconi, M., Scarpa, A., Taal, B., Kwekkeboom, D. J., Lopes, J. M., Perren, A., Nikou, G., Yao, J., Delle Fave, G. F., & O\u2019Toole, D. (2008). Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: Foregut, midgut, hindgut, and unknown primary. Neuroendocrinology, 87(1), 47\u201362. https:\/\/doi.org\/10.1159\/000111037","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10303_CR78","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1530\/EJE-14-0630","volume":"172","author":"T de Baere","year":"2015","unstructured":"de Baere, T., Deschamps, F., Tselikas, L., Ducreux, M., Planchard, D., Pearson, E., Berdelou, A., Leboulleux, S., Elias, D., & Baudin, E. (2015). GEP-NETS update: Interventional radiology: Role in the treatment of liver metastases from GEP-NETs. European Journal of Endocrinology, 172(4), R151-166. https:\/\/doi.org\/10.1530\/EJE-14-0630","journal-title":"European Journal of Endocrinology"},{"issue":"11","key":"10303_CR79","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/bjs.9262","volume":"100","author":"O Norlen","year":"2013","unstructured":"Norlen, O., Stalberg, P., Zedenius, J., & Hellman, P. (2013). Outcome after resection and radiofrequency ablation of liver metastases from small intestinal neuroendocrine tumours. British Journal of Surgery, 100(11), 1505\u20131514. https:\/\/doi.org\/10.1002\/bjs.9262","journal-title":"British Journal of Surgery"},{"issue":"1","key":"10303_CR80","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000443612","volume":"104","author":"Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Muller HH, Arnold R, Group PS","year":"2017","unstructured":"Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, Muller HH, Arnold R, Group PS. (2017). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results of long-term survival. Neuroendocrinology, 104(1), 26\u201332. https:\/\/doi.org\/10.1159\/000443612","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10303_CR81","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin, M. E., Pavel, M., Cwikla, J. B., Phan, A. T., Raderer, M., Sedlackova, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., Rindi, G., Langley, A., Martinez, S., Blumberg, J., Ruszniewski, P., Investigators C. (2014). Lanreotide in metastatic enteropancreatic neuroendocrine tumors. The New England Journal of Medicine, 371(3), 224\u2013233. https:\/\/doi.org\/10.1056\/NEJMoa1316158","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10303_CR82","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/onco.13633","volume":"26","author":"E Merola","year":"2021","unstructured":"Merola, E., Alonso Gordoa, T., Zhang, P., Al-Toubah, T., Pelle, E., Kolasinska-Cwikla, A., Zandee, W., Laskaratos, F., de Mestier, L., Lamarca, A., Hernando, J., Cwikla, J., Strosberg, J., de Herr, W., Caplin, M., Cives, M., & van Leeuwaarde, R. (2021). Somatostatin analogs for pancreatic neuroendocrine tumors: Any benefit when Ki-67 is >\/=10%? The Oncologist, 26(4), 294\u2013301. https:\/\/doi.org\/10.1002\/onco.13633","journal-title":"The Oncologist"},{"issue":"10022","key":"10303_CR83","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, H., Voi, M., Pacaud, L. B., Rouyrre, N., Sachs, C., Valle, J. W., Fave, G. D., Van Cutsem, E., Tesselaar, M., Shimada, Y., Oh, D. Y., \u2026 Pavel, M. E. (2016). Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet, 387(10022), 968\u2013977. https:\/\/doi.org\/10.1016\/S0140-6736(15)00817-X","journal-title":"Lancet"},{"issue":"6","key":"10303_CR84","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond, E., Dahan, L., Raoul, J. L., Bang, Y. J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., Chen, J. S., Horsch, D., Hammel, P., Wiedenmann, B., Van Cutsem, E., Patyna, S., Lu, D. R., Blanckmeister, C., Chao, R., & Ruszniewski, P. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England Journal of Medicine, 364(6), 501\u2013513. https:\/\/doi.org\/10.1056\/NEJMoa1003825","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10303_CR85","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/ajco.12571","volume":"12","author":"CT Liu","year":"2016","unstructured":"Liu, C. T., Chen, M. H., Chen, J. S., Chen, L. T., Shan, Y. S., Lu, C. H., Su, Y. L., Ku, F. C., Chou, W. C., & Chen, Y. Y. (2016). The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Asia-Pacific Journal of Clinical Oncology, 12(4), 396\u2013402. https:\/\/doi.org\/10.1111\/ajco.12571","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"7","key":"10303_CR86","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/annonc\/mdx193","volume":"28","author":"ME Pavel","year":"2017","unstructured":"Pavel, M. E., Baudin, E., Oberg, K. E., Hainsworth, J. D., Voi, M., Rouyrre, N., Peeters, M., Gross, D. J., & Yao, J. C. (2017). Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: Final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. Annals of Oncology, 28(7), 1569\u20131575. https:\/\/doi.org\/10.1093\/annonc\/mdx193","journal-title":"Annals of Oncology"},{"issue":"11","key":"10303_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz219","volume":"30","author":"MH Kulke","year":"2019","unstructured":"Kulke, M. H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J. W., De Herder, W. W., Pavel, M., Degtyarev, E., Brase, J. C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R. P., & Yao, J. C. (2019). A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of Oncology, 30(11), Article 1846. https:\/\/doi.org\/10.1093\/annonc\/mdz219","journal-title":"Annals of Oncology"},{"issue":"11","key":"10303_CR88","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1002\/onco.13885","volume":"26","author":"E Grande","year":"2021","unstructured":"Grande, E., Rodriguez-Antona, C., Lopez, C., Alonso-Gordoa, T., Benavent, M., Capdevila, J., Teule, A., Custodio, A., Sevilla, I., Hernando, J., Gajate, P., Molina-Cerrillo, J., Diez, J. J., Santos, M., Lanillos, J., & Garcia-Carbonero, R. (2021). Sunitinib and evofosfamide (TH-302) in systemic treatment-naive patients with grade 1\/2 metastatic pancreatic neuroendocrine tumors: The GETNE-1408 trial. The Oncologist, 26(11), 941\u2013949. https:\/\/doi.org\/10.1002\/onco.13885","journal-title":"The Oncologist"},{"issue":"11","key":"10303_CR89","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu, J., Shen, L., Bai, C., Wang, W., Li, J., Yu, X., Li, Z., Li, E., Yuan, X., Chi, Y., Yin, Y., Lou, W., Xu, N., Bai, Y., Zhang, T., Xiu, D., Wang, X., Yuan, Y., Chen, J., \u2026 Su, W. (2020). Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): A randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, 21(11), 1489\u20131499. https:\/\/doi.org\/10.1016\/S1470-2045(20)30493-9","journal-title":"Lancet Oncology"},{"issue":"5","key":"10303_CR90","doi-asserted-by":"publisher","first-page":"526","DOI":"10.21147\/j.issn.1000-9604.2023.05.09","volume":"35","author":"J Zhang","year":"2023","unstructured":"Zhang, J., Zhu, H., Shen, L., Li, J., Zhang, X., Bai, C., Zhou, Z., Yu, X., Li, Z., Li, E., Yuan, X., Lou, W., Chi, Y., Xu, N., Yin, Y., Bai, Y., Zhang, T., Xiu, D., Chen, J., \u2026 Xu, J. (2023). Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib. Chinese Journal of Cancer Research, 35(5), 526\u2013535. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2023.05.09","journal-title":"Chinese Journal of Cancer Research"},{"key":"10303_CR91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403991","author":"JA Chan","year":"2024","unstructured":"Chan, J. A., Geyer, S., Zemla, T., Knopp, M. V., Behr, S., Pulsipher, S., Ou, F. S., Dueck, A. C., Acoba, J., Shergill, A., Wolin, E. M., Halfdanarson, T. R., Konda, B., Trikalinos, N. A., Tawfik, B., Raj, N., Shaheen, S., Vijayvergia, N., Dasari, A., \u2026 Meyerhardt, J. A. (2024). Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. New England Journal of Medicine. https:\/\/doi.org\/10.1056\/NEJMoa2403991","journal-title":"New England Journal of Medicine"},{"key":"10303_CR92","doi-asserted-by":"crossref","unstructured":"Koenig AO, Reinecke J, Halfen J, Lang K, K\u00f6nig U, Tostmann R, Kirchhof N, Asendorf T, H\u00f6rsch D, Kr\u00f6cher A, Quante M, Ellenrieder V, Schulte N, Wirth T, Weich A, Apostolidis L, Krug S, Rinke A, Pavel MEJAoO: 1146MO Interim analysis of CABONEN: A multicenter phase II trial investigating cabozantinib in patients with advanced, low proliferative NEN G3. 2024.","DOI":"10.1016\/j.annonc.2024.08.1205"},{"issue":"9808","key":"10303_CR93","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Horsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., Oberg, K., Van Cutsem, E., Yao, J. C., Group R-S. (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet, 378(9808), 2005\u20132012. https:\/\/doi.org\/10.1016\/S0140-6736(11)61742-X","journal-title":"Lancet"},{"issue":"12","key":"10303_CR94","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., Grande, E., Van Cutsem, E., Seregni, E., Duarte, H., Gericke, G., Bartalotta, A., Mariani, M. F., Demange, A., Mutevelic, S., & Krenning, E. P. (2021). (177)Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncology, 22(12), 1752\u20131763. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6","journal-title":"Lancet Oncology"},{"issue":"10446","key":"10303_CR95","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh, S., Halperin, D., Myrehaug, S., Herrmann, K., Pavel, M., Kunz, P. L., Chasen, B., Tafuto, S., Lastoria, S., Capdevila, J., Garcia-Burillo, A., Oh, D. Y., Yoo, C., Halfdanarson, T. R., Falk, S., Folitar, I., Zhang, Y., Aimone, P., de Herr, W. W., & Ferone, D. (2024). [(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study. Lancet, 403(10446), 2807\u20132817. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3","journal-title":"Lancet"},{"issue":"11","key":"10303_CR96","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.2967\/jnumed.120.258772","volume":"62","author":"RV Parghane","year":"2021","unstructured":"Parghane, R. V., Bhandare, M., Chaudhari, V., Ostwal, V., Ramaswamy, A., Talole, S., Shrikhande, S. V., & Basu, S. (2021). Surgical feasibility, determinants, and overall efficacy of neoadjuvant (177)Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine, 62(11), 1558\u20131563. https:\/\/doi.org\/10.2967\/jnumed.120.258772","journal-title":"Journal of Nuclear Medicine"},{"issue":"6","key":"10303_CR97","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2967\/jnumed.120.244798","volume":"62","author":"T Binderup","year":"2021","unstructured":"Binderup, T., Knigge, U., Johnbeck, C. B., Loft, A., Berthelsen, A. K., Oturai, P., Mortensen, J., Federspiel, B., Langer, S. W., & Kjaer, A. (2021). (18)F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: A prospective 10-year follow-up study. Journal of Nuclear Medicine, 62(6), 808\u2013815. https:\/\/doi.org\/10.2967\/jnumed.120.244798","journal-title":"Journal of Nuclear Medicine"},{"issue":"4","key":"10303_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102386","volume":"9","author":"T Al-Toubah","year":"2024","unstructured":"Al-Toubah, T., Schell, M. J., Morse, B., Haider, M., Valone, T., & Strosberg, J. (2024). Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. ESMO Open, 9(4), Article 102386. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102386","journal-title":"ESMO Open"},{"issue":"2","key":"10303_CR99","doi-asserted-by":"publisher","first-page":"317","DOI":"10.20517\/cdr.2021.150","volume":"5","author":"N Hussain","year":"2022","unstructured":"Hussain, N., Das, D., Pramanik, A., Pandey, M. K., Joshi, V., & Pramanik, K. C. (2022). Targeting the complement system in pancreatic cancer drug resistance: A novel therapeutic approach. Cancer Drug Resistance, 5(2), 317\u2013327. https:\/\/doi.org\/10.20517\/cdr.2021.150","journal-title":"Cancer Drug Resistance"},{"issue":"3","key":"10303_CR100","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.18632\/oncotarget.13874","volume":"8","author":"HH Chang","year":"2017","unstructured":"Chang, H. H., Liu, Y. L., Lu, M. Y., Jou, S. T., Yang, Y. L., Lin, D. T., Lin, K. H., Tzen, K. Y., Yen, R. F., Lu, C. C., Liu, C. J., Peng, S. S., Jeng, Y. M., Huang, S. F., Lee, H., Juan, H. F., Huang, M. C., Liao, Y. F., Lee, Y. L., & Hsu, W. M. (2017). A multidisciplinary team care approach improves outcomes in high-risk pediatric neuroblastoma patients. Oncotarget, 8(3), 4360\u20134372. https:\/\/doi.org\/10.18632\/oncotarget.13874","journal-title":"Oncotarget"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-025-10303-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10303-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T07:01:45Z","timestamp":1764486105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-025-10303-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":100,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10303"],"URL":"https:\/\/doi.org\/10.1007\/s10555-025-10303-0","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}